Merck & Company (MRK) : Mondays money flow points at investors jumping to buy the stock on the weakness of price. $128.01 million worth of transactions were on upticks, whereas, the downticks accounted for $85.19 million worth of transactions. The net money flow was a positive $42.82 million and the uptick to downtick ratio was 1.5. However, the block trades showed a clear dominance of the bulls with a very healthy ratio of 3.18 in their favor. The net money flow into the stock was $45.92 million. The value of block trades done on downticks was only $21.1 million. The lack of interest in trading on downticks shows that the investors dont want to sell their holdings. The upticks accounted for $67.02 million of the total block trades, indicating continued buying interest on weakness, which bodes well for the future of the stock. Merck & Company (MRK) was trading at $59.02, down $0.61 during day. The stock slid -1.02% over the previous days close. For the week, the stock recorded -0.56% over the previous weeks close.
Merck & Co. Inc. is up 5.29% in the last 3-month period. Year-to-Date the stock performance stands at 13.64%. Merck & Co. Inc. has dropped 0.54% in the last five trading days, however, the shares have posted positive gains of 2.64% in the last 4 weeks. In a related news, The officer (Exe V-P, HR), of Merck & Co., Inc., Graddick Weir Mirian M had unloaded 45,000 shares at $57.96 per share in a transaction on July 5, 2016. The total value of transaction was $2,608,200. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Merck & Company (NYSE:MRK): On Mondays trading session , Opening price of the stock was $59 with an intraday high of $59.49. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $58.715. However, the stock managed to close at $59.02, a loss of 1.02% for the day. On the previous day, the stock had closed at $59.63. The total traded volume of the day was 8,769,171 shares.
Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. The Companys animal health products are sold to veterinarians, distributors and animal producers.